Business

CELLINK acquires Nanoscribe for €50M to buy into Two-Photon Polymerization

Swedish 3D bioprinter manufacturerCELLINK已经宣布收购两光子聚合(2pp)3D打印机制造商nanoscribe

Through the deal, worth €50 million in cash, shares and earn-outs, CELLINK is set to take full control of Nanoscribe, while integrating 2PP technology into its own to enable the fabrication of more lifelike soft tissues. Leveraging its new miniaturization capabilities, the firm also anticipates being able to reduce lead times and costs across its product portfolio, in addition to broadening its offering of consumables.

“With Nanoscribe’s state of the art 2PP technology, we will complement our product portfolio and offer a wider range of products to our amazing customers,” said Erik Gatenholm, CEO of CELLINK. “We are combining our strong, purpose driven growth agenda with trailblazing bioconverging technologies for the sake of improving health all around the world.”

“通过对Nanoscribe的战略收购,我们将进一步加强在3D生物打印细分市场中的市场领先地位。”

Filigree structures up to the millimeter range can be printed with the highest resolution. Photo via Nanoscribe.
Nanoscribe的2pp 3D打印技术可以制造超详细的微型结构(如图)。通过Nanoscribe的照片。

CELLINK’s ‘bioconvergence’ strategy

When CELLINK was established back in 2016, it was set up as a developer of 3D bioprinting technologies, and the firm has since launched six systems including the SLA-basedHolograph Xand six-printheadBIO X6。Recently, however, the firm has shifted its focus to expanding on its addressable markets and technological portfolio, while embarking on an acquisition-focused ‘bioconvergence’ strategy.

In order to work towards its stated ambition of “leveraging synergistic life science breakthroughs” to bring about medicinal advances, the companybought Scienion for €80 millionin August 2020. Essentially, the deal has since allowed CELLINK to increase its market penetration in the pharmaceutical field, and gain a foothold within the diagnostics sector.

在2021年3月,该公司然后获得了Mattek Corporationfor $68 million, in a move that provided it with access to new in-vitro technologies, with the potential to expedite its workflow and advance its 3D bioprinting research. Now, with its acquisition of Nanoscribe, CELLINK has also added 2PP to its portfolio, a technology that could enable it to grow into both the micro-optics and photonics sectors.

CELLINK's acquisition of Scienion is expected to be completed by the end of August 2020. Photo via CELLINK.
Cellink去年以8000万欧元的价格收购了Scienon,这是其更广泛的“生物对抗”战略的一部分。通过Cellink照片。

Detailing CELLINK’s €50m deal

In its latest acquisition agreement, CELLINK has agreed to buy all Nanoscribe’s outstanding shares on a cash and debt-free basis via a structured €50 million payment. Of the purchase price, €22.1 million is set to be paid in cash, with €11.9 million being provided in newly-issued shares and €16 million via performance-related earn-outs, contingent on the firm meeting its 2021-2023 financial targets.

Following the deal’s completion, Nanoscribe will remain under the same brand and leadership, although its financials will be consolidated into CELLINK’s from Q2 2021. For FY 2021, Nanoscribe is projecting a turnover of €15.4 million, and moving forwards, CELLINK expects to generate recurring revenue through its new implant, microneedle, membrane, and omics consumable product lines.

在Cellink上个月的AGM上,其董事会正式批准了此次收购,该公司表示,现在旨在“尽快合理地总结这笔交易”,并与Hengeler & Müller,,,,Duff & PhelpsandZaccoalready lined-up to advise on the transaction and oversee its completion.

将2pp和生物打印融合在一起

Founded in 2007 by scientists from theKarlsruhe技术学院(套件),Nanoscribe专门开发纳米,微型和中尺度3D打印机和材料。该公司的专有2PP技术使制造微小的超高分辨率对象,细节降至仅200纳米水平,并在光学和电子应用应用程序中发挥了巨大潜力。

通过获取Nanoscribe,Cellink有效地旨在成为行业中的第一个将2PP集成到现有的3D生物印刷设置中,并以亚细胞尺度发展血管微环境,这可能在细胞研究中有用,并且可以作为用于蜂窝研究的基础,并且可以作为一种基础。一系列新型实验室芯片设备。

根据该公司的更广泛的生物涉足策略,此举还有望将其研发进一步发展为现实的软组织体系结构,这些体系结构显示出更大的细胞活力。实际上,Cellink说,生命科学行业正在经历“非常令人兴奋的转变”,其中微型化的作用正在帮助减少遗传测序中的瓶颈。

Using its newly-acquired 2PP capabilities, the firm therefore stands to reduce the number of preparation steps required within single-cell genomics, accelerating its bioprinting workflow, and it has identified several “strong synergies” with Nanoscribe that will facilitate the “cross-functional adoption” of 2PP across its business.

“We take pride in our state-of-the-art 2PP technology, offering our customers the tools to materialize their ground-breaking ideas,” concluded Martin Hermatschweiler, CEO of Nanoscribe. “We very much look forward to joining the CELLINK Group, together exploring the possibilities with the 2PP technique, and delivering on the Group’s vision to create the future of medicine.”

要了解最新的3D印刷新闻,请不要忘记订阅3D打印行业通讯or follow us onTwitteror liking our page onFacebook

您是否正在寻找添加剂制造业的工作?访问3D Printing Jobsfor a selection of roles in the industry.

特色图像显示了一位持有微型nanoscribe-3D印刷的丝质丝结构的科学家。通过Nanoscribe的照片。